DME AWARE Study Defines Key Needs - Takeaways - MDSpire

DME AWARE Study Defines Key Needs

Presenting results from the DME AWARE Delphi Study at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, Baruch D. Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California, Irvine, described a set of consensus findings that point to unmet needs across the continuum of DME management, with particular emphasis on early intervention and noninvasive treatment options (Figure 1).

  • By

  • Jim Gallagher, senior managing editor

  • May 1, 2026

  • 5 min

Share

  • 1

    The DME AWARE Study identified key unmet needs in diabetic macular edema management, emphasizing early intervention and noninvasive therapies.

  • 2

    Approximately 60% of patients with diabetic macular edema remain untreated a year after diagnosis, highlighting significant treatment gaps.

  • 3

    Panelists favored noninvasive treatments over intravitreal therapy, especially for patients with mild or early-stage diabetic macular edema.

  • 4

    Consensus was reached on defining poor treatment response as less than a 10% reduction in central subfield thickness in diabetic macular edema.

  • 5

    The study revealed limitations of existing therapies, with 25-40% of patients not achieving optimal outcomes even with anti-VEGF agents.

Original Source(s)

DME AWARE Study Defines Key Needs

  • by Jim Gallagher, senior managing editor

  • May 1, 2026

Related Content

From risk factors to molecular targets: clinical associations and molecular docking insights into phthalate-associated diabetic retinopathy

What RVO May Reveal About Systemic Health

TriNetX data presented at Retina World Congress linked BRVO and CRVO with increased risks of stroke, myocardial infarction, and carotid disease.

Oculomics: Beyond the Buzzword

Joseph J. Pizzimenti, OD, FAAO, FORS, discusses the capabilities of oculomics in retina and neuro-ophthalmology,